Pacira BioSciences, Inc.PCRXEarnings & Financial Report
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
Revenue
$179.5M
Gross Profit
$145.2M
Operating Profit
$6.4M
Net Profit
$5.4M
Gross Margin
80.9%
Operating Margin
3.5%
Net Margin
3.0%
YoY Growth
6.5%
EPS
$0.12
Pacira BioSciences, Inc. Q3 FY2025 Financial Summary
Pacira BioSciences, Inc. reported revenue of $179.5M (up 6.5% YoY) for Q3 FY2025, with a net profit of $5.4M (up 103.8% YoY) (3.0% margin). Cost of goods sold was $34.3M, operating expenses totaled $138.9M.
Key Financial Metrics
| Total Revenue | $179.5M |
|---|---|
| Net Profit | $5.4M |
| Gross Margin | 80.9% |
| Operating Margin | 3.5% |
| Report Period | Q3 FY2025 |
Revenue Breakdown
Pacira BioSciences, Inc. Q3 FY2025 revenue of $179.5M breaks down across 5 segments, led by EXPAREL at $139.9M (77.9% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| EXPAREL | $139.9M | 77.9% |
| ZILRETTA | $29.0M | 16.1% |
| Iovera | $6.5M | 3.6% |
| Bupivacaine Liposome Injectable Suspension | $2.7M | 1.5% |
| Royalty | $1.5M | 0.8% |
Pacira BioSciences, Inc. Revenue by Segment — Quarterly Trend
Pacira BioSciences, Inc. revenue by segment across the last 4 reported quarters, showing how each business line (such as EXPAREL and ZILRETTA) has evolved quarter over quarter.
| Segment | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 |
|---|---|---|---|---|
| EXPAREL | $143.3M | $155.8M | $139.9M | $142.9M |
| ZILRETTA | $26.8M | $33.0M | $29.0M | $31.3M |
| Iovera | — | $7.0M | $6.5M | $5.6M |
| Bupivacaine Liposome Injectable Suspension | — | — | $2.7M | — |
| Royalty | — | — | $1.5M | — |
Pacira BioSciences, Inc. Annual Revenue by Year
Pacira BioSciences, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $726.4M).
| Year | Annual Revenue |
|---|---|
| 2025 | $726.4M |
| 2024 | $701.0M |
| 2023 | $675.0M |
| 2022 | $666.8M |
Pacira BioSciences, Inc. Quarterly Revenue & Net Profit History
Pacira BioSciences, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $177.4M | +5.0% | $2.9M | 1.6% |
| Q4 FY2025 | $196.9M | +5.1% | N/A | N/A |
| Q3 FY2025 | $179.5M | +6.5% | $5.4M | 3.0% |
| Q2 FY2025 | $181.1M | +1.7% | $-4.8M | -2.7% |
| Q1 FY2025 | $168.9M | +1.1% | $4.8M | 2.8% |
| Q4 FY2024 | $187.3M | +3.3% | N/A | N/A |
| Q3 FY2024 | $168.6M | +2.8% | $-143.5M | -85.1% |
| Q2 FY2024 | $178.0M | +5.0% | $18.9M | 10.6% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $178.0M | $168.6M | $187.3M | $168.9M | $181.1M | $179.5M | $196.9M | $177.4M |
| YoY Growth | 5.0% | 2.8% | 3.3% | 1.1% | 1.7% | 6.5% | 5.1% | 5.0% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $1.65B | $1.52B | $1.55B | $1.59B | $1.54B | $1.30B | $1.26B | $1.21B |
| Liabilities | $767.5M | $772.1M | $775.2M | $788.1M | $779.5M | $570.4M | $571.8M | $554.6M |
| Equity | $879.3M | $749.6M | $778.3M | $798.5M | $757.8M | $727.2M | $693.1M | $653.9M |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $53.2M | $53.9M | $33.1M | $35.5M | $12.0M | $60.8M | $43.7M |